Diabetes associated peptide amide fragment 8-37 R, with the CAS number 138398-61-5, is a synthetic peptide that plays a role in metabolic regulation and is associated with diabetes-related research. This peptide is derived from the proinsulin molecule and is known for its potential effects on insulin signaling and glucose metabolism. Characteristically, it exhibits a specific amino acid sequence that contributes to its biological activity, influencing pathways related to insulin sensitivity and secretion. The amide form indicates that the terminal amino group is modified, which can enhance stability and bioactivity. This peptide is often studied in the context of diabetes and metabolic disorders, providing insights into therapeutic approaches for managing these conditions. Its properties, such as solubility and stability, are influenced by its peptide structure, making it a subject of interest in pharmacological and biochemical studies aimed at understanding diabetes mechanisms and developing potential treatments.

diabetes associated peptide amide*fragment 8-37 R

138398-61-5: Diabetes associated peptide amide fragment 8-37 R, with the CAS number 138398-61-5, is a synthetic peptide that plays a role in metabolic regulation and is associated with diabetes-related research. This peptide is derived from the proinsulin molecule and is known for its potential effects on insulin signaling and glucose metabolism. Characteristically, it exhibits a specific amino acid sequence that contributes to its biological activity, influencing pathways related to insulin sensitivity and secretion. The amide form indicates that the terminal amino group is modified, which can enhance stability and bioactivity. This peptide is often studied in the context of diabetes and metabolic disorders, providing insights into therapeutic approaches for managing these conditions. Its properties, such as solubility and stability, are influenced by its peptide structure, making it a subject of interest in pharmacological and biochemical studies aimed at understanding diabetes mechanisms and developing potential treatments.

The effect of IAPP (8-37) (mouse, rat), an amylin receptor antagonist, on the ANP release was attenuated in streptozotocin-treated rats.

Amylin (8-37) (mouse, rat)

Amylin (8-37), rat, an analog of IAPP, blocks insulin's effects on muscle glucose uptake and glycogen storage.

Amylin (8-37), rat

<p>Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool</p>

CAS 138398-61-5

diabetes associated peptide amide*fragment 8-37 R

Amylin (8-37) (mouse, rat)

Ref: 01-4030346

Amylin (8-37), rat

Ref: TM-TP1233

Amylin (8-37), rat

Ref: 3D-PP50572